Keywords: solvay, updates, progress, belgium, hiked, its, expenditures

Solvay updates on R&D progress

Article | 24 February 2003

Print This

Belgium's Solvay hiked its expenditures on R&D by 22% in 2002 as itpursued Phase III trials of cilansetron, a treatment for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in